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Cowpea mosaic virus (CPMV) is a well-charac-
terized nanoparticle that has been used for
a variety of nanobiotechnology applications.
CPMV interacts with several mammalian cell
lines and tissues in vivo. To overcome natural
CPMV targeting and redirect CPMV particles
to cells of interest, we attached a folic acid-
PEG conjugate by using the copper-catalyzed
azide-alkyne cycloaddition reaction. PEGylation
of CPMV completely eliminated background
binding of the virus to tumor cells. The PEG-
folate moiety allowed CPMV-specific recogni-
tion of tumor cells bearing the folate receptor.
In addition, by testing CPMV formulations with
different amounts of the PEG-FA moiety dis-
played on the surface, we show that higher-
density loading of targeting ligands on CPMV
may not be necessary for efficient targeting to
tumor cells. These studies help to define the
requirements for efficiently targeting nanopar-
ticles and protein cages to tumors.
INTRODUCTION
The ability to target tumors and deliver therapeutics to spe-
cific locations in the body is a primary goal in cancer medi-
cine. Tumor-specific targeting has the potential to reduce
adverseeffectsand increase the therapeuticbenefitof highly
toxicchemotherapies [1]. Tumor-targetingstrategies include
the use of various types of molecular and supramolecular
scaffolds such as liposomes [2], iron oxide nanoparticles
[3], silica-gold nanoshells [4], highly branched macromole-
culessuchasdendrimers [5,6],proteincages[7], andviruses
[8–11]. Ligands capable of targeting tumors such as anti-
bodies, peptides, or small molecules are typically attached
to the exterior surface. In many cases, drugs or contrast
agents can also be encapsulated inside the particles in order
tocombine targetedcell killingwith intravital imaging [12–16].1152 Chemistry & Biology 14, 1152–1162, October 2007 ª2007Recently viruses and protein cages have been studied in
the development of tumor-specific targeting strategies [8,
17]. These multivalent protein assemblies have the advan-
tages of simple production, monodisperse size and struc-
ture, and surfaces that are compatible with circulation
in vivo [10, 18–20]. One such particle is cowpea mosaic
virus (CPMV), a plant virus that grows in the common cow-
pea plant (Vigna unguiculata) and forms a 31 nm diameter
icosahedral structure [21, 22]. CPMV grows to very high
yields in infectedplants,and thepurification issimpleand in-
expensive. In addition,CPMV isnonpathogenic for humans,
and the products derived from plant virus culture are not
contaminated with animal cells or viruses [23, 24]. CPMV
particles are highly stable to extremes of temperature, pH,
and a variety of organic solvents such as DMSO [21, 25].
Surface modification of CPMV particles for targeting
purposes has been performed by genetic and chemical
means [26–31]. Chemical modification of CPMV surface
lysine residues using fluorescent dye-labeled N-hydroxy-
succinimide (NHS) esters or sulfhydryl groups usingmalei-
mide and haloacetamide reagents has been extensively
characterized [29, 32]. Surface carboxylate groups may
also be modified for specific attachment [33]. Recently,
CPMV particles were shown to be stable to the conditions
of the copper(I)-catalyzed azide-alkyne cycloaddition
(CuAAC) reaction, dramatically increasing the variety of
ligands that may be efficiently conjugated to the capsid
surface [34, 35].
Although it is a plant pathogen and does not replicate in
animal cells, CPMV has been shown to interact with a va-
riety of cell types both in vitro and in vivo [17, 36]. Fluores-
cently labeled CPMV interacts with vascular endothelial
cells when injected intravenously, allowing for a clear res-
olution of vascular structures in a variety of organs, while
PEG-coated CPMV does not [36]. Interestingly, CPMV in-
teracts specifically with a 54 kD membrane protein found
in mammalian cells, and this interaction is also blocked by
PEG coating of the virus [37]. These studies demonstrate
that CPMVhas significant potential for use in targeting and
imaging of both normal vasculature and tumors in vivo but
also underscores the need for cell-specific retargeting of
the capsid.Elsevier Ltd All rights reserved
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Folate Targeting of CPMV NanoparticlesOne of the best-characterized ligands to be exploited
for targeting tumor cells is the vitamin folic acid (FA). FA
plays an essential role in human growth and development
and at the cellular level in cell division and DNA synthesis
[38]. Uptake of FA into cells is mediated by the folate
receptor (FR), and binding of FA to FR initiates receptor-
mediated endocytosis and internalization of FA [39, 40].
Normally expression of FR on cells is low; however, the
demand for FA increases during cellular activation and
proliferation. Indeed, FR expression is upregulated on a
variety of human tumors, including cancers of the ovary,
kidney, uterus, testis, brain, lung, and myelocytic blood
cells [12, 41–43]. Upregulation of FR has also been corre-
lated with poor disease outcome [44]. Thus, FA has been
studied as a promising targeting ligand for cancer detec-
tion, imaging, and treatment [45].
Several nanoparticle formulations have used FA-based
targeting strategies. The derivatization of liposomes with
FA has been the most intensively investigated thus far
[13, 14, 46]. Other nanoparticle formulations employing
FA-targeting include FA-coated gadolinium nanoparticles
that were shown to increase uptake in tumors, suggesting
the possibility of neutron capture therapy [47], poly-ami-
doamine dendrimers (PAMAM) conjugated to FA [6, 48],
and core-shell nanostructures decorated with FA [49].
The FA-targeting strategy has also been applied to gold
nanoparticles [50], pegylated micelles [51], and adenovi-
ruses [10] in an attempt to reach FR-expressing cells.
PEG spacers have also been used to facilitate binding of
the conjugated FA to cell-surface receptors [14, 51–54].
Nevertheless, precise control of attachment of targeting
ligands at the nanoscale, as well as establishment of the
relationship between ligand density and target cell recog-
nition, has not been achieved.
Several attached large molecules such as peptides, an-
tibody ligands, tumor receptor ligands, and transferrin,
have been used to target viral nanoparticles and protein
cages [29, 35, 55], but the efficiency of cellular targeting
using capsid-arrayed small molecule ligands has been
less well studied. We report here the chemical attachment
of FA, PEG, and PEG-conjugated FA to CPMV by using
the CuAAC reaction in order to direct the capsid specifi-
cally to tumor cells. The ability of the PEGmolecules to in-
hibit natural CPMV-cell surface interactions and the ability
of FA-modified CPMVs to bind to tumor cells was studied
by confocal microscopy and flow cytometry-based bind-
ing assays. In addition, CPMV-based formulations that
kept the amount of PEG constant and varied the loading
of the FA ligand were evaluated for their ability to interact
with FR-expressing cells in order to test the hypothesis
that polyvalent binding might be advantageous for cell-
specific targeting of CPMV.
RESULTS
Previous studies have shown that CPMV recognizes and
is taken up by a variety of mammalian cell types [36, 37].
To first ask whether CPMV conjugated directly to FA could
redirect this natural targeting, an NHS ester of FA wasChemistry & Biology 14, 1152–11conjugated to surface lysines onCPMV. A parallel reaction
performed under identical conditions with fluorescein-
NHS resulted in the attachment of 100 ± 10 dyes per par-
ticle; we assume that the analogous folate conjugation
gave a similar result [56, 57]. The natural uptake of
CPMV is significant [36], and CPMV-FA particles showed
no measurable increase in binding to FR-expressing KB
cells in comparison to unmodified CPMV particles as
measured by flow cytometry binding analysis and cell
uptake studies (data not shown). Thus, the natural cellular
interactions of CPMV needed to be modified in order to
achieve FR-specific targeting.
We previously showed that PEG (3,400 Da) inhibits the
natural targeting and uptake of CPMV [36]. In addition,
the importance of a PEG spacer for efficient cellular recog-
nition of FA-conjugated nanoparticles has also been pre-
viously noted [2]. To accommodate tailored loading of
both PEG and FA on CPMV particles, a relatively short
(500 Da) PEG chain was introduced as shown in Figure 1.
A monodisperse azide-PEG-amine was coupled to the
NHS ester of folic acid to give the FA-azide 2a. The corre-
sponding polyvalent alkyne nanoparticle was obtained by
reacting CPMV with a large excess of the alkynyl NHS
ester reagent 1. This procedure has been shown to acylate
150–200 of the exposed lysine side chain amines of CPMV
[56] and was chosen to provide an excess of available
surface alkyne groups for subsequent attachment. The
use of the CuAAC ligation reaction eliminates the need
for protecting group manipulations and allows for repro-
ducible attachments to be achieved with a minimum
amount of material.
FA derivatives are known to form aggregates at high
concentrations [58], and there are some indications that
too many FA molecules displayed on a surface can inhibit
binding to the target receptor, perhaps because of such
aggregation [59]. To address this phenomenon, we limited
the density of PEG-FAs on CPMV by using a relatively low
concentration of azide derivatives in the CuAAC bioconju-
gation step. An estimate of the loading was obtained by
performing a parallel reaction by using N3-PEG-fluores-
cein (2b) with CPMV-alkyne under identical conditions,
as we have previously described [57]. This transformation
provided a value of 60 ± 6 molecules per virus for the
attachment of PEG-Fluorescein or PEG-FA, where a
1 mg/ml CPMV solution translates to a folic acid concen-
tration of 10 mM.
The integrity of the conjugated virus preparations was
verified by analytical size exclusion chromatography
(Superose 6), which also showed by a slightly smaller elu-
tion volume that the CPMV-(PEG-FA)60 conjugate appears
to be slightly larger than unmodifiedCPMV (Figure 2A). It is
possible that the early elution of CPMV-(PEG-FA)60 could
also be caused by altered interaction of PEG-FA moiety
with the column material in comparison to the unmodified
particle (designated CPMV-WT). The sharpness of the
peaks for CPMV-(PEG-FA)60 in comparison to CPMV-
WT suggests that the modification of the particles within
the population is relatively uniform on a per-particle basis.
This uniformity was supported by transmission electron62, October 2007 ª2007 Elsevier Ltd All rights reserved 1153
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Folate Targeting of CPMV NanoparticlesFigure 1. Synthesis of the PEG-Folic Acid Conjugates
Scheme for synthesis of FA-conjugated CPMV.microscopy (TEM) studies (Figures 2E and 2F) of nega-
tively stained samples, which confirmed that the CPMV-
(PEG-FA)60 particles were intact and showed no evidence
of aggregation. Visual analysis of the samples showed that
100% of the CPMV-(PEG-FA)60 particles exhibited a halo-
like structure on the surface of the particle that appeared
to be uniform within the population and which was absent
in unmodified CPMV (Figures 2E and 2F).
Successful PEG-FA conjugation was further confirmed
by gel electrophoresis and western immunoblotting. Fig-
ure 2B shows the large (L) and small (S) capsid proteins
of wild-type and PEG-FA-derivatized CPMV; unlike larger
PEG chains used in previous studies [60], the small PEG-
FAmoiety used here shifted the positions of the fully dena-
tured S or L bands only slightly toward higher molecular
weight. Western immunoblots appear in Figures 2C and
2D, by using higher concentrations of capsid protein.
The use of anti-CPMV antibody showed the L and S sub-
units as well as minor amounts of higher molecular weight
species that arise from incomplete denaturation of the
durable CPMV capsid (Figure 2C). After attachment of
PEG-FA, the higher molecular weight bands increased in
intensity, presumably because the FA-derivatized protein
subunits weremore prone toward aggregation or resistant
to denaturation (Figure 2C). Anti-FA antibody showed all of1154 Chemistry & Biology 14, 1152–1162, October 2007 ª2007 Ethe bands from CPMV-(PEG-FA)60 to bear FA (Figure 2D).
Of the five surface lysines found on CPMV, two dominate
the acylation reactivity of the particle—one each on the S
(lysine 38) and L (lysine 99) subunits [56, 61]. The average
of 60 PEG-FA chains per particle may therefore be
assumed to be distributed largely among the 120 sites
provided by these two residues on the capsid exterior.
The ability of the relatively short (500 Da) PEG chains to
inhibit the natural targeting of CPMVwas assessed by flow
cytometry. Two tumor cell lines, KB and HeLa, were used
for these studies. KB, a human nasopharyngeal carci-
noma cell line, has been widely used in tumor-targeting
studies due to its high expression of FR and affinity for
FA [42, 45, 48, 62–64]. HeLa cells, a well-established epi-
theloid cervical carcinoma, have been reported to express
less FR than KB cells. The cellular uptake of CPMV parti-
cles in KB or HeLa cells after 2 hr incubation at 37C was
analyzed by fluorescence microscopy (Figure 3). As previ-
ously described, unmodified CPMV showed significant
uptake in HeLa and KB cell lines (Figures 3A and 3D), while
the decoration of CPMV with PEG inhibited this phenom-
enon (Figures 3B and 3E). Both types of cells also showed
increased uptake of FA-conjugated viruses compared to
unmodified CPMV (Figures 3C and 3F). Interestingly, up-
take of CPMV-(PEG-FA)60 in HeLa cells appeared as anlsevier Ltd All rights reserved
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Folate Targeting of CPMV Nanoparticlesevenly dispersed fluorescence in the cytoplasm, while
CPMV uptake in KB cells showed a more punctate distri-
bution of the virus throughout the cells. CPMV is naturally
targeted to lysosomes [36], although the endocytic path-
way used to reach this compartment is unknown. The up-
take of FR in either cell type is not well defined and has
been shown to involve both clathrin-mediated and caveo-
lin-mediated endocytic pathways. Differences between
uptake patterns in each cell type could be due to differ-
ences in receptor expression level (e.g., saturation of the
clathrin-mediated pathway in HeLa cells spilling into the
Figure 2. Virus Integrity Assessed by Size Exclusion Chroma-
tography, Western Blot, and TEM
(A) Size exclusion FPLC analysis of CPMV-PEG-FA and WT-CPMV.
(B) Coomassie stain ofWT-CPMV (1) and CPMV-(PEG-FA)60 (2), show-
ing small (S) and large (L) capsid subunit proteins.
(C–D) Western blots of WT-CPMV (1) and CPMV-(PEG-FA)60 at higher
concentration (2). Left panel, detection using rabbit anti-CPMV anti-
body. Right panel, detection using mouse anti-folic acid antibody. L,
large subunit; and S, small subunit.
(E–F) Typical TEM image of WT-CPMV (E) and CPMV-(PEG-FA)60 (F),
showing intact particles. The bar represents 200 nm.Chemistry & Biology 14, 1152–11caveolae pathway or vice versa), or due to differences in
the localization of endocytic vesicles or the trafficking pat-
tern of vesicle recycling between the two cell types [63, 65,
66]. Nevertheless, our data indicate that the endocytic
pathway used for uptake and trafficking of CPMV-PEG-
FA is modified in comparison to CPMV-WT.
Differences in cell-surface binding were measured by
flow cytometry, where virus binding and subsequent steps
were carried out at 4C in order to minimize endocytosis.
CPMV-(PEG-FA)60 bound to KB cells much better than to
HeLa cells (94% and 22%, respectively, relative to cells
alone) (Figures 4A and 4B, solid histograms), and both
cell types interacted hardly at all with CPMV-PEG lacking
the terminal FA moiety (1.6% and 0.7% to KB and HeLa
cells, respectively) (Figures 4A and 4B). These results
are consistent with the difference in the expression of
FR receptors on the two cell types (approximately 2.8 3
105 receptors per cell for KB cells versus 4-fold fewer
receptors per cell for HeLa [67, 68]). Further details are
provided in the Supplemental Data and Figure S1 avail-
able with this article online.
To further show that the interaction between CPMV-
PEG-FA and tumor cells was due to specific interactions
between the particles and FR on cells, the ability of free
folic acid to compete for binding of CPMV-(PEG-FA)60 to
KB cells was assessed by flow cytometry. In the experi-
ment shown in Figure 5A, free folic acid at greater than
10 mM substantially inhibited CPMV-(PEG-FA)60 binding,
and less than 1 mM folic acid had no effect. CPMV-
(PEG-FA)60 was used at a concentration of 17 nM in parti-
cles, or 1 mM total FA. Nonlinear regression analysis
(Prism, GraphPad, Inc., San Diego, CA) of a representative
experiment revealed an IC50 value of 2.75 mM. The aver-
age IC50 of four separate experiments was 4.9 mM (Fig-
ure 5A). If each folate unit on CPMV acted as a free fo-
late molecule and each virus-cell contact was made by
a single FA-FR interaction, the IC50 value would, by defini-
tion, be equal to the virus-displayed FA concentration of 1
mM. Thus, FA displayed on the capsid surface binds with
similar affinity on a per-folate basis than free folic acid.
On a per-particle basis, the avidity of CPMV-(PEG-FA)60
for KB cells is much stronger (by approximately 300 times)
than free FA.
To further explore whether controlling FA loading at the
nanoscale could influence interaction with FR, three differ-
ent versions of CPMV-PEG-FA were formulated that had
an equal loading of PEG but varied in the number of FA
units at the end of the PEG chains. Separate portions of
CPMV-alkyne were reacted with azide-PEG-FA and two
different combinations of azide-PEG-FA and azide-PEG-
amine, giving rise to the attachment of 60, 35, and 20
PEG-FA units per particle (Figure 1, bottom). These are
designated CPMV-(PEG-FA)60, CPMV-(PEG-FA)35, and
CPMV-(PEG-FA)20, respectively. Comparative western
blots using identical amounts of virus particles confirmed
the relative loading values by Spot Density Analysis (Alpha
Innotech, San Leandro, CA) (Figure S2A). While little differ-
ence in the cell uptake of each of these particles was
observed at saturating conditions, titration of binding62, October 2007 ª2007 Elsevier Ltd All rights reserved 1155
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Folate Targeting of CPMV NanoparticlesFigure 3. Fluorescent Microscopy of Monolayers of HeLa and KB Cells
Cells were incubated with the indicated virus particles (37C, 2 hr), followed by permeabilization and treatment with anti-CPMV antibody and thenwith
a green fluorescent secondary antibody conjugate. Nuclei are stained with DAPI (blue). Top, HeLa cells; bottom, KB cells. Scale bar, 10 mm.revealed a clear difference in binding that correlated with
the loading of FA per particle (Figure S2B). Moreover,
in a competition assay using free FA to inhibit binding, in
each case, approximately the same concentration of
free FA was required to disrupt binding of the particles
to KB cells as was presented on the virus surface (Fig-
ure 5B). In other words, in no case was a substantial
per-folate polyvalent effect observed, but in all cases,
the folate-decorated particles bound substantially better
than free folic acid molecules alone.
DISCUSSION
In this work, we demonstrate the specific binding and
endocytosis of a FA-derivatized CPMV particle by cells
bearing FR. Direct, controlled chemical conjugation of a
monodisperse PEG-FA moiety to the CPMV surface by
copper (I)-catalyzed azide-alkyne cycloaddition (CuAAC)
was efficient and resulted in the attachment of amaximum1156 Chemistry & Biology 14, 1152–1162, October 2007 ª2007of 60 ± 6 molecules of FA per particle. Wild-type CPMV
exhibited significant binding, which was eliminated by
the conjugation of the relatively short PEG chains to the
virus surface. The addition of the FA moiety then allowed
the particles to be recognized specifically by the tumor
cell lines. Modulating the extent of FA loading using the
CuAAC reaction demonstrated excellent control of parti-
cle modification at the nanoscale and correlated with
tumor cell recognition. These studies suggest that CPMV
nanoparticles can be effectively redirected by surface
conjugation to ligands of interest, allowing specific uptake
into tumors while avoiding nonspecific uptake into normal
cells.
At least two factors may contribute to the inability of
HeLa or KB cells to specifically recognize FA directly con-
jugated to the CPMV capsid (as opposed to FA being
displayed on the end of PEG chains). The simplest expla-
nation is that endogenous and potentially multivalent
CPMV-cell surface interactions are of higher affinity thanFigure 4. Measurement of Virus Binding
to Tumor Cells Using Flow Cytometry
(A) Binding of CPMV to HeLa tumor cells.
(B) Binding of CPMV to KB tumor cells. The
peaks from left to right are cells only (dotted
histogram), CPMV-PEG (short dashed lines),
WT-CPMV (long dashed lines), and CPMV-
(PEG-FA)60 (filled histograms), respectively.Elsevier Ltd All rights reserved
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Folate Targeting of CPMV Nanoparticlesthe FA-FR interaction. Second, the conjugated FA units
may simply be rendered inaccessible to FR by virtue of
being attached to the rigid capsid structure by a short
tether; previous reports have noted steric impediments
to binding in other settings [14, 52, 53]. Alternatively, if en-
docytosis is initiated by multivalent binding, rather than
a single-point contact (as has long been known for certain
carbohydrate receptors [69, 70]), there may be aminimum
distance that adjacent FAs need to achieve before such
a process is initiated. The PEG linker can address both
potential deficiencies, and studies are in progress to at-
tempt to distinguish between these possibilities. It should
be noted that the PEG linker used here is significantly
shorter than has been previously employed for FA nano-
particles [52, 53, 64].
Our studies coupling 20–60 PEG-FA moieties to CPMV
resulted in targeting that compares favorably to other
FA-conjugated nanoparticle formulations. For example,
conjugation of FA to PAMAM dendrimers resulted in load-
ing of about 2.5 molecules of FA residues per dendrimer,
due to an undesired reaction occurring between the car-
boxylic acid groups of FA and the amine groups of the
dendrimer. In this case, no binding enhancement was
observed: a concentration of 30 nM of free FA reduced
by 50% the amount of association to KB cells reached
by 30 nM of the dendrimer-FA conjugate [5, 48]. Coupling
Figure 5. Competition of CPMV-PEG-FA Using Free FA
(A) CPMV-PEG-FA bearing 60 FA/particle (1 mM FA) was incubated
with KB cells in the presence of increasing amounts of FA as indicated.
Error bars represent the mean ± SD of triplicate experiments.
(B) Competition of CPMV-(PEG-FA)20 (gray), CPMV-(PEG-FA)35 (white
bars), or CPMV-(PEG-FA)60 was performed with increasing amounts of
FA as indicated. In each case, the concentration of virus particles was
17 nM, giving rise to the following concentrations of displayed FA:
CPMV-(PEG-FA)20 = 0.33 mM FA; CPMV-(PEG-FA)35 = 0.6 mM FA;
CPMV-(PEG-FA)60 = 1 mM FA.Chemistry & Biology 14, 1152–11of FA to 10 nm Au nanoparticles has also been reported
[50], but only 20% of the KB cells exposed to the nanopar-
ticles actively took up the FA-conjugate. This uptake could
be suppressed by 2 mM free FA.
PEGylation of CPMV, even with the small 500 Da mate-
rial here, resulted in effective suppression of the particle’s
natural cellular interactions. The strategy has been used
previously inmany other studies by our groups and others.
For example, multifunctional PEGylated micelles conju-
gated to FA and carrying the antitumor drug adriamycin
showed significant increase in cytotoxicity compared to
nontargeted micelles. However, longer incubation times
also induced significant cytotoxicity when nontargeted
micelles were used, suggesting that PEGylation was not
sufficient in blocking nonspecific binding of the micelles
to tumor cells [51]. Attempts have also beenmade to retar-
get adenovirus particles to KB cells [10]. The adenovirus
surface was modified with FA-PEG conjugate (24% occu-
pancy), resulting in a 40% increase in transfection effi-
ciency over nontargeted pegylated virus. Nevertheless,
the pegylated adenovirus was still able to transduce cells
via its natural coxsackie-adenovirus receptor (CAR), sug-
gesting that the degree of PEGylation was not sufficient to
effectively retarget the virus.
One drawback in most chemical nanoparticle formula-
tions is the lack of control over the spatial distribution on
the outer shell of the ligand of interest. A sophisticated ra-
tional design of ligand orientation and stoichiometry would
allow for the creation of a polyvalent scaffold that en-
hances the targeting properties of the nanoparticle and
offers the possibility of cell targeting with lower concentra-
tions of targeting molecules than would be possible for the
monomeric form [71]. The increased binding of CPMV-
PEG-FA over free FA (factor of approximately 2 per FA,
or 120 per particle) is not sufficient to clearly indicate the
existence of polyvalent (simultaneous multipoint) interac-
tions [72] with FR, compared to other known examples
using carbohydrates and cell surface lectins [73–77] or
liposome-displayed anthrax peptides and receptors [78].
In part, thismay be due to the nature of the ligand-receptor
pair, since more substantial avidity effects were observed
by using CPMV displaying carbohydrate moieties [28, 79]
(E. Kaltgrad and M.G. Finn, personal communication). In-
terestingly, a substantial polyvalent effect has recently
been quantified by SPR measurements of binding affinity
for FA displayed on dendrimers [78, 80]. While the more
flexible nature of the dendrimer scaffold may better match
cellular receptor patterns, as has been previously hypoth-
esized [78], the target is also different (protein immobilized
on SPR chips versus cell-surface receptors), and compe-
tition with free monovalent folate was not reported in the
dendrimer case [80]. For CPMV-PEG-FA, the roughly lin-
ear trend of free FA inhibition with variation of PEG-FA
loading further suggests that monovalent FA-FR inter-
actions are dominant but also that local concentration of
the FA ligand plays a role in binding of cells to the polyva-
lent scaffold. It seems likely that the effective off-rate of
the particle is slowed by facile reassociation with FR re-
ceptors brought about by the high local concentration of62, October 2007 ª2007 Elsevier Ltd All rights reserved 1157
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necessary to provide enough increased avidity and endo-
cytosis to allow for effective tumor targeting [81].
Prior attempts to target tumors with displayed FA have
yielded mixed results depending on the tumor site [47, 82,
83]. Endothelial cell targeting has also been widely stud-
ied in order to reach the tumor vasculature [15, 84].
Thus, a combination of targeting moieties could enhance
the specificity of nanoparticles to tumors in vivo. Toward
these ends, the construction and in vivo testing of more
sophisticated particles, taking advantage of the precise
control of amino acid side-chain positioning and reactivity
to install PEGs and tethered targeting moieties, is in prog-
ress in our laboratories.
SIGNIFICANCE
The ability to specifically target therapeutics and
imaging modalities to tumors is an important goal in
biomedicine. Viruses and protein cage nanoparticles
have proven utility in this area, however many of these
materials have natural cellular interactions. CPMV in
particular provides tremendous imaging resolution of
normal and tumor vasculature; however, the particles
have significant affinity for cell-surface proteins.
Thus, any natural in vivo interaction of the nanoparticle
must bemasked and the particle retargeted to a tumor
ligand of interest. In this article, we use copper (I) cata-
lyzed azide-alkyne cycloaddition chemistry to pre-
cisely attach a defined number of folic acid tumor li-
gands, while redirecting the natural specificity of the
particles by coating the remaining surface of the par-
ticles with low molecular-weight polyethylene glycol.
The resulting particles are effectively retargeted
specifically to the folic-acid receptor. The density of
ligands may be controlled at the nanoscale, and com-
petitive binding versus free folic acid was shown to
track linearly with the density of folate attached to the
nanoparticle scaffold. The high local concentration of
folic acid on the capsid surface enables these particles
to be targeted efficiently to cell-surface FR receptors.
To our knowledge, this is the first time that small-mol-
ecule ligands have been successfully used to provide
targeting specificity for virus-based nanoparticles.
EXPERIMENTAL PROCEDURES
All reagents, unless otherwise specified, were purchased from com-
mercial suppliers and used without further purification. Bifunctional
N3-PEG-NH2 [N3(CH2CH2O)11CH2CH2NH2, MW 570, PDI = 1.0] was
obtained from Polypure, Inc. Copper(I) triflate was prepared according
to literature procedures [85].
Propagation of CPMV in Plants
The primary leaves of Kentucky cowpea plants (Vigna unguiculata)
were mechanically inoculated as 10 day old seedlings, bearing two pri-
mary leaves and with secondary leaves just beginning to show. Virus
stocks were initiated from pCP1 and pCP2 plasmid cDNAs encoding
full-length copies of the two RNA moieties of CPMV, RNA-1, and
RNA-2, respectively. Carborundum was first dusted onto the leaves
to aid in the wounding process. At approximately 3 weeks post inocu-1158 Chemistry & Biology 14, 1152–1162, October 2007 ª200lation, the symptomatic leaves were harvested, weighed, and frozen at
70C until virus purification. The virus was purified from the infected
leaves by a method described elsewhere [86].
Synthesis of N3-PEG-FA
FA-NHS ester was prepared from FA according to literature proce-
dures [2]. FA-NHS (100 mg, 0.19 mmol) in anhydrous DMSO (10 ml)
was treated with N3-PEG-NH2 (50 mg, 0.09 mmol), and the mixture
was stirred while warming gently (ca. 35C) for 20 hr. DMSO was
removed under high vacuum at RT. The residue was treated with
CH2Cl2, and the solids were scraped gently from the walls of the flask.
The mixture was sonicated to form a slurry, which was transferred to a
fritted disk, andwashed thoroughlywith diethyl ether, CH2Cl2, andTHF.
The residual dark orange solid was dried and extracted with water until
the aqueous extract was colorless. The aqueous fractions were com-
bined and evaporated under vacuum to yield N3-PEG-FA (compound
2) as viscous orange oil (60 mg, 0.06 mmol, 66%). 1H NMR (200
MHz, D2O): d 8.59 (s, 1H), 7.52 (d, 2H), 6.64 (d, 2H), 4.48 (s, 1H),
4.15 (m, 2H), 3.58–3.35 (m, 40), 2.35–2.20 (m, 12H). An analogous
procedure was employed for the synthesis of N3-PEG-fluorescein.
Preparation of CPMV-Alkyne
Compound 1 (50 mg, 0.20 mmol) was dissolved in DMSO (1 ml) and
added to a solution of wild-type CPMV (5 ml, 7 mg/ml, 75 mM in protein
subunits, 0.1 M phosphate buffer [pH 7.0]). The mixture was gently ag-
itated at RT for 15 hr and purified by sucrose gradient fractionation
(10%–40% sucrose in 0.1 M [pH 7.0] phosphate buffer, Beckman
SW-28 Ti rotor, 28000 rpm, 3 hr). The intact virus was collected as
a pale white band under intense illumination on a gradient fraction col-
lector and subjected to ultracentrifugation (Beckman 50.2 Ti rotor,
42000 rpm, 3 hr) to form a colorless pellet. The solution was decanted
and the colorless pellet was dissolved under N2 with sufficient buffer
(Tris-Cl, 0.1 M [pH 8.0]) to obtain a concentration of 7.3 mg/ml.
Conjugations to CPMV-Alkyne
The following reaction protocol was carried out in an inert atmosphere
(N2) glove box with O2 level kept below 6 ppm until the final gel filtration
step. For each of the three N3-PEG-FA loading levels, a 2ml Eppendorf
centrifuge tube was charged with CPMV-alkyne (7.3 mg/ml, 110 ml)
and buffer (Tris-Cl, 0.1 M [pH 8.0], 260, 250, 220 ml, respectively).
Degassed aqueous solutions of N3-PEG-FA (25 mM; 10, 20, 50 ml, re-
spectively) and N3-PEG-NH2 (25 mM; 40, 30, 0 ml, respectively) were
added simultaneously to the virus solution and mixed by gentle agita-
tion. Thus, the total azide and PEG concentrations were kept constant
for each of the three reactions, and the amount of FA versus amine
caps on the PEG chains were varied. A solution of copper(I) triflate
(100 mM, CH3CN, 50 ml) was combined with a solution of sulfonated
bathophenanthroline (100 mM in 100 mM Tris-Cl [pH 8.0], 100 ml)
(We subsequently learned that Tris-Cl slightly inhibits the CuAAC reac-
tion relative to HEPES buffer, and so the latter is now recommended) to
form a catalyst of the formulation 3. An aliquot of the catalyst mixture
(16 ml) was added to the tube containing the virus. The reaction mixture
was immediately placed on a rotisserie for continuous agitation, and
kept under N2 at RT for 15 hr. The product (designated CPMV-PEG-
FA) was purified by three passages through size exclusion gel-filtration
columns (BioRad, p-100), which removed all residual catalyst and ex-
cess N3-PEG-FA. The integrity of the virus was verified by analytical
size exclusion chromatography (Superose 6) and transmission elec-
tron microscopy (TEM, samples stained with 0.2% uranyl acetate;
images acquired on a 100 Kv Philips Tecnai electron microscope).
Conjugations of N3-PEG-NH2 and N3-PEG-Fluorescein to CPMV-
alkyne were performed in the same manner by using the following
reagents: CPMV-alkyne (7.3 mg/ml, 110 ml), buffer (Tris-Cl, 0.1 M [pH
8.0], 250 ml), N3-PEG-NH2, or N3-PEG-Fluorescein (25 mM, 20ml). Virus
concentrations were determined by UV-vis spectroscopy: at 0.1 mg/
ml, CPMV gives a standard absorbance of 0.8 at 260 nm. The average
molecular weight of the CPMV virion is 5.6 3 106.7 Elsevier Ltd All rights reserved
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FA-NHS (31 mg, 58 mmol) was dissolved in DMSO (1 ml) and added to
a solution of wild-type CPMV (5ml, 3 mg/ml, 32 mM in protein subunits,
0.1 M phosphate buffer [pH 7.0]). The mixture was gently agitated at
RT for 15 hr and purified by sucrose gradient fractionation (10%–
40% sucrose in 0.1 M [pH 7.0] phosphate buffer, Beckman SW-28 Ti
rotor, 28000 rpm, 3 hr). The intact virus was collected as a pale white
band under intense illumination on a gradient fraction collector and
subjected to ultracentrifugation (Beckman 50.2 Ti rotor, 42000 rpm,
3 hr) to form a colorless pellet. The solution was decanted, and the
colorless pellet was dissolved with sufficient buffer (Tris-Cl, 0.1 M
[pH 8.0]) to obtain a concentration of 5.0 mg/ml. CPMV-FA was char-
acterized in the manner described above for CPMV-alkyne + azide
conjugates.
Western Blotting
To detect CPMV, protein bands were visualized by Western blotting
with anti-CPMV IgG (purified from rabbit polyclonal antisera on a pro-
tein G column; Amersham Pharmacia, Uppsala, Sweden) and diluted
1:1000 in blocking buffer (PBS, 5% normal goat serum, 0.05%
Tween20). ImmunoPure goat anti-rabbit IgG, peroxidase conjugated,
diluted 1:20,000 (Pierce, Rockford, IL) was used as secondary anti-
body. Folic acid conjugated to CPMV was detected by western blot-
ting with mouse anti-Folic acid monoclonal antibody (Sigma-Aldrich,
St. Louis, MO) diluted 1:1000 in blocking buffer (PBS, 5% normal
goat serum, 0.05% Tween20). Goat anti-mouse peroxidase conju-
gated, diluted 1:20,000 (Pierce, Rockford, IL) was used as secondary
antibody. In both cases, detection of peroxidasewas carried out by us-
ing SuperSignal West Pico Chemiluminescent Substrate (Pierce,
Rockford, IL).
Cell Culture and Binding Studies
HeLa cells and KB cells, the latter a human nasopharyngeal epidermal
carcinoma [62], were grown continuously as a monolayer by using
FA-free RPMI1640 medium (GIBCO, Invitrogen, Carlsbad CA) contain-
ing 10% heat-inactivated fetal bovine serum (FBS), penicillin (50 units/
ml), streptomycin (50 mg/ml), and 2 mM L-glutamine at 37C in a 5%
CO2/95% air humidified atmosphere. The concentration of folic acid
was 5–6 nM in FA-free medium containing serum, close to the natural
physiologic concentration (5–30 nM) [52, 87]. On the day before each
experiment, the medium was replaced with FA-free RPMI 1640 con-
taining all the supplements mentioned above, except 10% FBS.
Measurement of Virus Binding to HeLa and KB Cells Using
Flow Cytometry
HeLa and KB cells, grown overnight in FA-depleted medium, were
treated with trypsin, counted, and distributed in 100 ml portions into
a 96-well V-bottom shaped plate at a concentration of 5 3 106 cells/
ml. Ten micrograms of different virus preparations were added to
each well and the cells were incubated on ice at 4C for 1 hr. The cells
were thenwashed four timeswith ice-cold PBS buffer containing 1mM
EDTA and 25mMHEPES (pH 7.5), centrifuged at 1,600 rpm for 6min at
4C. Rabbit anti-CPMV primary antibodywas then added to the cells in
a 100 ml volume, and the cells were incubated on ice at 4C for 30 min
and washed as above. The same procedure was then repeated with
goat anti-rabbit IgG AlexaFluor 488 conjugated antibody (Invitrogen,
Carlsbad, CA), with incubation conducted in the dark. Finally, the cells
were fixed with 2% formaldehyde in PBS buffer containing 1mMEDTA
and 25 mM HEPES (pH 7.5). The samples were then analyzed with
a FACS Calibur instrument (BD Biosciences, Franklin Lakes, NJ). Ap-
proximately 40,000 events were collected for each sample, and the
data were analyzed with FlowJo software (Tree Star, Inc, Ashland,
OR). Binding and competition data were further analyzed by nonlinear
regression analysis (Prism, GraphPad, Inc.). Independent control
experiments established that the PEG-conjugated CPMV was recog-
nized with approximately the same efficiency as native CPMV by the
anti-CPMV antibody.Chemistry & Biology 14, 1152–11Cellular Uptake of the FA-Conjugated Virus in HeLa
and KB Cells
Cells were seeded in a 12-well plate containing 12 mm sterile glass
coverslips at 1 3 105 cells/well and grown for 48 hr as previously de-
scribed. On the day of the experiment, cells were washed once with
FA-depleted medium, and 10 mg of different virus preparations were
added to each well, and the cells were incubated at 37C in a 5%
CO2/95% air humidified atmosphere for 2 hr. Cells were then washed
four times with FA-depleted medium to remove unbound virus, on
a rocker at room temperature for five minutes. Cells were then fixed
with 4% paraformaldehyde in PBS for 20 min. After four washes with
PBS buffer, cells were permeabilized with 0.1% Triton X-100 in PBS
for 15 min. Nonspecific binding was blocked by incubating the cells
in 5% goat serum in PBS for 1 hr. Rabbit anti-CPMV antibody was
added to the cells in 1% goat serum, 0.1% Triton X-100 in PBS, and
cells were incubated at room temperature for 45 min with gentle agita-
tion. Unbound antibody was then removed by washing four times with
PBS. Goat anti-rabbit IgG AlexaFluor 488 conjugated antibody (Invitro-
gen) was added in 1% goat serum in PBS, and cells were gently agi-
tated for a further 35 min. During the last 5 min of secondary antibody
incubation, cell nuclei were stained by adding 100 ml of 40,6-diamidino-
2-phenylindole (DAPI 1:1000 dilution in water). Cells were then washed
four times with PBS, and coverslips covered with cells were mounted
on slides with Vecta Shield mounting medium (Vector Laboratories).
Cells were imaged by using a Nikon Eclipse TS100 microscope, with
a 1003 oil objective.
Competition Assay
KB cells, grown overnight in FA-depleted medium, were treated with
trypsin, counted, and distributed in 100 ml portions into a 96-well
V-bottom shaped plate at a concentration of 5 3 106 cells/ml. Ten
micrograms of CPMV-PEG-FA was added to the cells together with
different concentrations of free FA, ranging from 750 mM to 1 nM. Cells
were then treated as described above, and the samples were analyzed
using flow cytometry. The competition assay was also carried out with
CPMV-PEG-FA that had been synthesized so that different amounts of
PEG-FA conjugate were displayed on the surface of the virus.
Supplemental Data
Supplemental Data include further characterization of CPMV-PEG-FA
binding, including comparisons of CPMV particles with different load-
ings of FA, and are available at http://www.chembiol.com/cgi/content/
full/14/10/1152/DC1/.
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